# Second-line Treatment of Metastatic Colorectal Cancer

Source: https://onco.cc/trials/nct06242067/  
OnCo record `nct06242067` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of trifluridine/tipiracil in colorectal cancer, run by Qilu Hospital of Shandong University, now recruiting.

## Summary

Second-line Treatment of Metastatic Colorectal Cancer is a phase 2, interventional study registered as NCT06242067 by Qilu Hospital of Shandong University, with a registry enrolment figure of 50 participants, started 2023-04-23 and due to reach its primary completion in 2024-12. Interventions recorded: Trifluridine/tipiracil. Conditions listed: Metastatic Colorectal Cancer. Primary outcome: progression-free survival(PFS). Colorectal eligibility wording from the registry: "Histologically or cytological proven metastatic or recurrent adenocarcinoma of the colon or rectum". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Also known as: BEV-TASIRI
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT06242067
- Phase: 2
- Setting: Irinotecan in Combination With Trifluridine-tipiracil and Bevacizumab in Pre-treated Metastatic Colorectal Cancer
- Sponsor: Qilu Hospital of Shandong University
- Enrolled: 50

## Sources

- ClinicalTrials.gov NCT06242067: https://clinicaltrials.gov/study/NCT06242067

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/)
- drugs: [Trifluridine/tipiracil](https://onco.cc/drugs/trifluridine-tipiracil/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06242067.json